Menu
Not yet recruiting NCT07310186

Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

— Observational Diffuse Large B Cell Lymphoma (DLBCL)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: observational study.
Who it may be relevant to
Registry conditions: Diffuse Large B Cell Lymphoma (DLBCL). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy: A Multi-center, Retro- and Prospective, Observational, Real-World Study

Overview

Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great significance, as it can guide clinicians in developing better and more tailored treatment strategies for patients in the future. Therefore, we plan to conduct this real-world study titled "Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy", aiming to obtain real-world data from the Chinese population.

Detailed description

This is a retro- and prospective, observational study

Interventions

  • Other observational study
    this is an observational study, we do not interfere with treatment strategies

Primary outcome measures

  • complete response rate [Time frame: through study completion, an average of 2 years]

Eligibility criteria

Inclusion criteria

  • Patients diagnosed with DLBCL
  • Age ≥18 years
  • Prior treatment with a polatuzumab vedotin (pola)-containing regimen and confirmed disease progression (refractory/relapsed) after this therapy.
  • Availability of complete electronic medical records and ability to be contacted via telephone.
  • Full understanding of the study, voluntary participation, and willingness to sign the informed consent form.

Exclusion criteria

  • Patients who have not received pola-based regimen treatment.
  • Incomplete electronic medical records or unreachable by telephone.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07310186 · PUMCH-NHL-022

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗